Aims: Atopic dermatitis (AD) is a chronic and relapsing inflammatory dermatitis characterized by pruritic and eczematous skin lesions. Here, we investigated the therapeutic effect of the fruit flavonoid naringenin on DNFB induced atopic dermatitis mice model.
Main Methods: AD-like skin lesion was induced by repetitive skin contact with DNFB in NC/Nga mice and the effects of the fruit flavonoid naringenin were evaluated on the basis of histopathological findings of skin, ear swelling and cytokine production of CD4(+)T cells.
Key Findings: Intraperitoneal injection of naringenin for one week after DNFB challenge significantly lowered ear swelling and improved back skin lesions. In addition, naringenin significantly suppressed production of interferon-gamma (IFN-γ) by activated CD4(+) T cells and serum IgE level. Furthermore, naringenin reduced DNFB-induced infiltration of eosinophils, mast cells, CD4(+) T cells, and CD8(+) T cells in skin lesions.
Significance: Naringenin may suppress the development of AD-like skin lesions in DNFB-treated NC/Nga mice by reducing IFN-γ production of activated CD4(+) T cells, serum IgE levels and infiltration of immune cells to skin lesion.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.lfs.2013.07.027 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Roads to remission: evolving treatment concepts in type 2 inflammatory diseases.
EClinicalMedicine
February 2025
Institute of Laboratory Medicine and Pathobiochemistry, Molecular Diagnostics, Philipps University Marburg, Marburg, Germany.
Unlabelled: Non-communicable diseases (NCDs) characterised by type 2 inflammation, including asthma, allergic rhinitis, chronic rhinosinusitis with nasal polyps, atopic dermatitis, food allergies and eosinophilic esophagitis, are increasing in prevalence worldwide. Currently, there is a major paradigm shift in the management of these diseases, towards the concept of disease modification and the treatment goal remission, regardless of severity and age. Remission as a treatment goal in chronic inflammatory NCDs was first introduced in rheumatoid arthritis, and then adopted in other non-type 2 inflammatory diseases.
View Article and Find Full Text PDFCOVID-19 related epigenetic changes and atopic dermatitis: An exploratory analysis.
World Allergy Organ J
January 2025
Department of Dermatology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Background: While epidemiological data suggest a connection between atopic dermatitis (AD) and COVID-19, the molecular mechanisms underlying this relationship remain unclear.
Objective: To investigate whether COVID-19-related CpGs may contribute to AD development and whether this association is mediated through the regulation of specific genes' expression.
Methods: We combined Mendelian randomization and transcriptome analysis for data-driven explorations.
Case Report: Baricitinib improved alopecia areata in a pediatric patient with atopic dermatitis.
Front Pediatr
January 2025
Department of Dermatology, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang Province, China.
Alopecia areata (AA) is a common non-scarring hair loss condition whose specific pathogenesis is not yet fully understood. In children, AA often co-occurs with atopic dermatitis (AD), complicating treatment. Here, we report the case of a child with myasthenia gravis who had severe AA and moderate AD.
View Article and Find Full Text PDFAssessment of information quality in the largest Danish Facebook group on atopic diseases: a mixed bag of help and harm.
Front Allergy
January 2025
Department of Public Health, Environment, Occupation, and Health, Aarhus University, Aarhus, Denmark.
Background: Patient education is an important part of the management of atopic diseases such as allergic rhinitis, atopic dermatitis, and asthma. Given the increasing reliance on social media platforms such as Facebook for health-related discourse, there are concerns about the accuracy and quality of the shared information.
Aim: The aim of this study was to categorize and assess the quality of the information shared within the largest Danish Facebook group focusing on atopic diseases.
New horizons in the treatment of psoriasis: Modulation of gut microbiome.
Heliyon
January 2025
Department of Medical Microbiology, Tehran University of Medical Sciences, Tehran, Iran.
The last decennia have witnessed spectacular advances in our knowledge about the influence of the gut microbiome on the development of a wide swathe of diseases that extend beyond the digestive tract, including skin diseases like psoriasis, atopic dermatitis, acne vulgaris, rosacea, alopecia areata, and hidradenitis suppurativa. The novel concept of the gut-skin axis delves into how skin diseases and the microbiome interact through inflammatory mediators, metabolites, and the intestinal barrier. Elucidating the effects of the gut microbiome on skin health could provide new opportunities for developing innovative treatments for dermatological diseases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!